{"id":209227,"name":"RX BIO, INC.","slug":"rx-bio-inc","state":"TN","country":"United States of America","description":"Biomedical research and development","totalSpending":160000,"filings":11,"yearlySpending":[{"year":2021,"income":90000},{"year":2022,"income":70000},{"year":2023,"income":0}],"issues":["BUD","HCR"],"firms":["ERVIN GRAVES STRATEGY GROUP, LLC"],"lobbyists":["JAMES ERVIN","COLBY MILLER","JOHN DONNELLY","JOE KASPER","ALLISON FEIKES"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support","Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support","Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support","Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support","Promote RxBio's biomedical research and advancements among Congressional, Department of Defense and other federal stakeholders, with primary focus on the FY22 budget cycle and securing federal support"],"years":[2021,2022,2023]}